Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug612 | COVID-19 convalescent plasma treatment Wiki | 0.45 |
drug614 | COVID-19 diagnostic test Wiki | 0.45 |
drug765 | Clinical Trial Matching Wiki | 0.45 |
Name (Synonyms) | Correlation | |
---|---|---|
drug1289 | Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC) Wiki | 0.45 |
drug615 | COVID-19 e-package: Psychological wellbeing for healthcare workers Wiki | 0.45 |
drug3877 | modification of the planned therapeutic management Wiki | 0.45 |
drug1735 | Ketotifen 1 MG Wiki | 0.45 |
drug617 | COVID-19 exposure Wiki | 0.32 |
drug610 | COVID-19 convalescent plasma Wiki | 0.20 |
drug2687 | Questionnaire Administration Wiki | 0.13 |
Name (Synonyms) | Correlation | |
---|---|---|
D002583 | Uterine Cervical Neoplasms NIH | 0.63 |
D002285 | Carcinoma, Intraductal, Noninfiltrating NIH | 0.45 |
D002277 | Carcinoma NIH | 0.45 |
Name (Synonyms) | Correlation | |
---|---|---|
D002278 | Carcinoma in Situ NIH | 0.45 |
D016889 | Endometrial Neoplasms NIH | 0.45 |
D004938 | Esophageal Neoplasms NIH | 0.45 |
D010051 | Ovarian Neoplasms NIH | 0.45 |
D013274 | Stomach Neoplasms NIH | 0.45 |
D014594 | Uterine Neoplasms NIH | 0.45 |
D014625 | Vaginal Neoplasms NIH | 0.45 |
D012878 | Skin Neoplasms NIH | 0.45 |
D044584 | Carcinoma, Ductal NIH | 0.45 |
D018270 | Carcinoma, Ductal, Breast NIH | 0.45 |
D009423 | Nervous System Neoplasms NIH | 0.45 |
D007680 | Kidney Neoplasms NIH | 0.45 |
D016543 | Central Nervous System Neoplasms NIH | 0.45 |
D014846 | Vulvar Neoplasms NIH | 0.45 |
D005909 | Glioblastoma NIH | 0.45 |
D008113 | Liver Neoplasms NIH | 0.45 |
D007822 | Laryngeal Neoplasms NIH | 0.45 |
D013736 | Testicular Neoplasms NIH | 0.45 |
D002292 | Carcinoma, Renal Cell NIH | 0.32 |
D012004 | Rectal Neoplasms NIH | 0.32 |
D018281 | Cholangiocarcinoma NIH | 0.32 |
D018358 | Neuroendocrine Tumors NIH | 0.32 |
D010190 | Pancreatic Neoplasms NIH | 0.26 |
D006258 | Head and Neck Neoplasms NIH | 0.26 |
D003110 | Colonic Neoplasms NIH | 0.22 |
D008175 | Lung Neoplasms NIH | 0.18 |
D009369 | Neoplasms, NIH | 0.08 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0003002 | Breast carcinoma HPO | 1.00 |
HP:0030079 | Cervix cancer HPO | 0.63 |
HP:0002896 | Neoplasm of the liver HPO | 0.45 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0008069 | Neoplasm of the skin HPO | 0.45 |
HP:0012114 | Endometrial carcinoma HPO | 0.45 |
HP:0100650 | Vaginal neoplasm HPO | 0.45 |
HP:0100006 | Neoplasm of the central nervous system HPO | 0.45 |
HP:0010788 | Testicular neoplasm HPO | 0.45 |
HP:0030731 | Carcinoma HPO | 0.45 |
HP:0009726 | Renal neoplasm HPO | 0.45 |
HP:0012174 | Glioblastoma multiforme HPO | 0.45 |
HP:0030416 | Vulvar neoplasm HPO | 0.45 |
HP:0100615 | Ovarian neoplasm HPO | 0.45 |
HP:0010784 | Uterine neoplasm HPO | 0.45 |
HP:0100751 | Esophageal neoplasm HPO | 0.45 |
HP:0004375 | Neoplasm of the nervous system HPO | 0.45 |
HP:0006753 | Neoplasm of the stomach HPO | 0.45 |
HP:0030075 | Ductal carcinoma in situ HPO | 0.45 |
HP:0100605 | Neoplasm of the larynx HPO | 0.45 |
HP:0005584 | Renal cell carcinoma HPO | 0.32 |
HP:0100634 | Neuroendocrine neoplasm HPO | 0.32 |
HP:0100743 | Neoplasm of the rectum HPO | 0.32 |
HP:0030153 | Cholangiocarcinoma HPO | 0.32 |
HP:0002894 | Neoplasm of the pancreas HPO | 0.26 |
HP:0012288 | Neoplasm of head and neck HPO | 0.26 |
HP:0003003 | Colon cancer HPO | 0.22 |
HP:0100526 | Neoplasm of the lung HPO | 0.18 |
HP:0002664 | Neoplasm HPO | 0.08 |
Navigate: Correlations HPO
There are 5 clinical trials
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.
Description: CTE Accrual
Measure: Proportion of patients Eligible for CTE versus Actual CTE Time: Through study completion, an average of 1 yearDescription: OS
Measure: Impact of CTE on Overall Survival (OS), estimated by Kaplan-Meier and Cox multivariable survival analysis Time: 4 yearsDescription: PFS
Measure: Impact of CTE on Progression-Free Survival (PFS), estimated by Kaplan-Meier and Cox multivariable survival analysis Time: 4 yearsDescription: To identify barriers to accruals to clinical trials, as measured and reported by a questionnaire
Measure: Identification of Barriers to CTE Time: Through study completion, an average of 1 yearDescription: To Analyze Individual Standard of Care Chemotherapy Utilization (nominal), across treatment lines (numeric); data will be combined and aggregated to report chemotherapy utilization rate (%).
Measure: Real World Data Analytics Time: Through study completion, an average of 1 yearDescription: VTB Use Rate
Measure: Virtual Tumor Board Utilization Time: Through study completion, an average of 1 yearDescription: Time to CTE
Measure: Time from Intervention to Actual CTE (months) Time: Through study completion, an average of 1 yearThis study investigates the impact of COVID-19 pandemic on out-of-pocket costs, lost wages, and unemployment in patients with breast cancer undergoing breast surgery. Post-mastectomy reconstructive patients are at high risk for financial toxicity (adverse effects of escalating health care cost on well-being). The goal of this study is to collect information about financial costs patients may have as a result of surgical treatment for cancer with or without breast reconstruction and to learn if COVID-19 affects patient costs of breast reconstruction. This may help researchers demonstrate the financial consequences of undergoing breast surgery.
Description: Will be measured by the Comprehensive Score for financial Toxicity questionnaire. Summary statistics including mean, standard deviation, median, and range for continuous variables, and frequency count and percentage for categorical variables will be provided. Various subgroup analyses may occur. In these cases, continuous variables will be compared using the two-sample t-test and categorical variables will be compared using chi-squared test or Fisher's exact test. Multivariate regression analysis will be performed to account for confounding and to increase the robustness of any causal inference.
Measure: Prevalence of financial toxicity Time: Up to 1 year after completion of studyDescription: Summary statistics including mean, standard deviation, median, and range for continuous variables, and frequency count and percentage for categorical variables will be provided. Various subgroup analyses may occur. In these cases, continuous variables will be compared using the two sample t-test and categorical variables will be compared using chi-squared test or Fisher's exact test. Multivariate regression analysis will be performed to account for confounding and to increase the robustness of any causal inference.
Measure: Correlation between economic disruption from coronavirus disease 2019 (COVID-19) and financial toxicity Time: Up to 1 year after completion of studyDescription: Will be assessed using the Short Form-12 survey. Summary statistics including mean, standard deviation, median, and range for continuous variables, and frequency count and percentage for categorical variables will be provided. Various subgroup analyses may occur. In these cases, continuous variables will be compared using the two-sample t-test and categorical variables will be compared using chi-squared test or Fisher's exact test. Multivariate regression analysis will be performed to account for confounding and to increase the robustness of any causal inference.
Measure: Relationship between financial toxicity and patient reported quality of life Time: Up to 1 year after completion of studyDescription: Will be assessed using the Breast-Q survey. Summary statistics including mean, standard deviation, median, and range for continuous variables, and frequency count and percentage for categorical variables will be provided. Various subgroup analyses may occur. In these cases, continuous variables will be compared using the two-sample t-test and categorical variables will be compared using chi-squared test or Fisher's exact test. Multivariate regression analysis will be performed to account for confounding and to increase the robustness of any causal inference.
Measure: Relationship between financial toxicity and patient reported satisfaction with breast reconstruction Time: Up to 1 year after completion of studyThe current infection with the Coronavirus SARS-CoV-2 (COVID-19) is an exceptional health situation which requires an adaptation of our management practices in gynecological oncology. Data from the literature suggest that infection with Coronavirus is serious in subjects with cancer with a risk of severe form 5 times higher than that of the population without cancer and a risk of death multiplied by 8. In addition, the risk of infection would be 3 times greater in case of cancer. Faced with the COVID-19 epidemic, the investigator must organize themselves to ensure continuity in the treatment of patients with gynecological cancer but also adapt our practices in the management (CPR, teleconsultation, adaptation of treatment or even postponement of treatment). The objective of the High Council of Public Health is to be able to ensure adequate oncological care avoiding any potential loss of chance concerning the care of cancer: people affected must, despite the pandemic, have care allowing the same level of curability (localized cancers) or the same life expectancy (advanced cancers). This must be done by limiting as much as possible the impact on the organization of the service, the organization of patient follow-up and the psychological impact that these possible modifications could have. The hypotheses of our study are that the exceptional health situation linked to this pandemic leads to a change in the care of patients with gynecological cancer associated with a psychological impact and increased anxiety of patients during their care. Despite the extent of the pandemic, very little existing data makes it possible to define recommendations with a sufficient level of evidence.
Description: modification of the planned therapeutic management
Measure: percentage of patients with a change in the planned therapeutic management (surgery, chemotherapy, radiotherapy, hormone therapy) Time: Day OThis single arm, multicenter study provides the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) administered at home by a home health nursing provider for patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer who are currently receiving pertuzumab (Perjeta) and trastuzumab (Herceptin) by intravenous administration (P+H IV). The main objective is to enable continuity of care during the COVID-19 pandemic. This study will enroll approximately 400 participants with HER2+ breast cancer who have completed concurrent chemotherapy with P+H IV and are currently receiving or will be receiving maintenance therapy with pertuzumab and trastuzumab. Participants will receive treatment every 3 weeks and continue treatment unless early cessation is necessary due to disease recurrence, disease progression, unacceptable toxicity or participant withdrawal. Only participants with HER2+ early breast cancer will receive PH FDC SC to complete 18 cycles of dual blockade, including the P+H IV they received prior to enrolling in this study. The Sponsor may decide to terminate the study when the COVID-19 pandemic is no longer a risk for this patient population.
The objective of our study was to evaluate the expected cardioprotective effects of ketotifen due to its activity as an iron-chelating agent previously uncovered by us in the in vitro chemical test which included in the study, when used in patients receiving anthracyclines for the treatment of breast cancer. The study was a randomized : , prospective controlled trial : , and the patients were identified by coded numbers to maintain privacy. Eligible patients (111) fulfilled the criteria. Control Group: 55 patients received their standard therapy (anthracycline-containing chemotherapy without ketotifen). Ketotifen Group: 56 patients received anthracycline-containing chemotherapy plus ketotifen as a cardioprotective agent. Ketotifen will be given orally as one tablet (1 mg/tablet) 3 times daily, before and during the chemotherapeutic cycle for 6 cycles of treatment. Blood samples were obtained from all patients, and echocardiography two times for each patient at baseline and after 6 months (EF%).
Description: the serum levels of LDH, CK-MB, troponin I, TIBC, ferritin, anti-cardiolipin IgG, and, iron were done
Measure: prophylaxis effect of Ketotifen on patient's hearts during the treatment of anthracyclines Time: 6 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports